InvestorsHub Logo
Followers 285
Posts 31200
Boards Moderated 0
Alias Born 07/06/2012

Re: John_Langston post# 136670

Thursday, 11/27/2014 12:43:02 PM

Thursday, November 27, 2014 12:43:02 PM

Post# of 400048

That will be obsolete before it get to market if it ever does.


ROTFLMMFAO!!!!! uh huh sure thing! LOL LOL!!

Elite Pharmaceuticals Press Release for: Tuesday, September 09, 2014

ELITE PHARMACEUTICALS RELEASES POSITIVE TOP LINE HUMAN ABUSE LIABILITY DATA FOR ELI-200, AN OPIOID ABUSE DETERRENT PRODUCT


HAL study compared subjective effects of drug liking, drug high and good drug effects between ELI-200 and the comparator formulation in non-dependent recreational drug users

Northvale, New Jersey, Tuesday, September 09, 2014: Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the ELI-200 product. ELI-200 is an undisclosed abuse deterrent opioid product for pain.

The study results demonstrated statistically significant (p <.0001) lower measures of drug liking, drug high and good drug effects for Elite’s manipulated (crushed) ELI-200 when compared to the manipulated (crushed) drug listed comparator product and found 91.9% of the subjects experienced increased drug liking with the comparator product compared to ELI-200 in non-dependent recreational drug users when administered intranasally. The study also found 80.6% of the subjects experienced a decrease in drug liking with the intranasal crushed ELI-200 in comparison to the administration of oral intact ELI-200.

Fear Uncertainty and Doubt FUD It Ain't Going To Work Here Anymore. Notice the lack of question mark.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News